論文

査読有り
2006年2月

Mutational analysis of TP53 and p21 in familial and sporadic ovarian cancer in Japan

GYNECOLOGIC ONCOLOGY
  • T Amikura
  • ,
  • M Sekine
  • ,
  • Y Hirai
  • ,
  • S Fujimoto
  • ,
  • M Hatae
  • ,
  • Kobayashi, I
  • ,
  • T Fujii
  • ,
  • Nagata, I
  • ,
  • K Ushijima
  • ,
  • K Obata
  • ,
  • M Suzuki
  • ,
  • M Yoshinaga
  • ,
  • N Umesaki
  • ,
  • S Satoh
  • ,
  • T Enomoto
  • ,
  • S Motoyama
  • ,
  • K Nishino
  • ,
  • K Haino
  • ,
  • K Tanaka

100
2
開始ページ
365
終了ページ
371
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1016/j.ygyno.2005.09.010
出版者・発行元
ACADEMIC PRESS INC ELSEVIER SCIENCE

Objective. To investigate whether somatic mutations in cell cycle checkpoint genes, TP53 and p21, are involved in the development of ovarian cancer with or without BRCA1 germline mutation.
Methods. We analyzed somatic genetic alterations of TP53 and p21 in 46 ovarian cancer patients with BRCA1 germline mutations and 93 sporadic patients, using direct sequencing for the entire coding sequences in TP53 and p21.
Results. TP53 somatic mutations were detected in 25 of the 46 BRCA1 cases and 40 of the 93 sporadic cases (54.3% vs. 43.0%). In contrast, p21 somatic mutations were detected in I of the 46 BRCA1 cases and 2 of the 93 sporadic cases (2.2% vs. 2.2%). TP53 mutations in sporadic cases more frequently occurred in exons 6-11 than those in cases with germline BRCA1 mutations (84.4% vs. 56.3%: P = 0.013). The proportion of sporadic cases with TP53 mutations in non-serous tumors (e.g. endometrioid, clear cell, or mucinous) was significantly lower than that in serous tumors (18.5% vs. 53.0%: P = 0.0038). However, there was no significant difference between the proportion of BRCA1 cases with TP53 mutation in non-serous and in serous tumors (37.5% vs. 57.9%).
Conclusions. Our results suggest that somatic mutation of TP53 plays less of a role in the carcinogenesis of sporadic non-serous tumors than in that of sporadic serous tumors or BRCA1-related tumors. Furthermore, p21 somatic mutation appears to be less involved in the development of ovarian cancer than TP53 somatic mutation. (c) 2005 Elsevier Inc. All rights reserved.

Web of Science ® 被引用回数 : 7

リンク情報
DOI
https://doi.org/10.1016/j.ygyno.2005.09.010
Web of Science
https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000235022800025&DestApp=WOS_CPL
ID情報
  • DOI : 10.1016/j.ygyno.2005.09.010
  • ISSN : 0090-8258
  • Web of Science ID : WOS:000235022800025

エクスポート
BibTeX RIS